A comprehensive evaluation of polygenic score methods across

cohorts in psychiatric disorders

Authors:

Guiyan Ni,[1] Jian Zeng,[1] Joana A Revez,[1] Ying Wang,[1] Tian Ge,[2] Restaudi Restaudi,[1]

Jacqueline Kiewa,[1] Dale R Nyholt,[3] Jonathan R I Coleman,[4] Jordan W Smoller,[5,2,6]

Schizophrenia Working Group of the Psychiatric Genomics Consortium,[7]

Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium,[8]

Jian Yang,[1] Peter M Visscher,[1] Naomi R Wray[1,9]

1. Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, 4072,

Australia

2. Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Massachusetts General

Hospital, Boston, MA, 02114, US

3. Faculty of Health, School of Biomedical Sciences, Centre for Genomics and Personalised

Health, Queensland University of Technology, Brisbane, Queensland, 4000, Australia

4. Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology,

and Neuroscience, King's College London, London, SE58AF United Kingdom

5. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, 02114, US

6. Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, 02142, US

7. A list of members and affiliations appears in the Supplementary Data.

8. A list of members and affiliations appears in the Supplementary Data.

9. Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, 4072,

Australia

Correspondence:

*Naomi R Wray: naomi.wray@uq.edu.au

Abstract:

Polygenic scores (PGSs), which assess the genetic risk of individuals for a disease, are

calculated as a weighted count of risk alleles identified in genome-wide association studies

(GWASs). PGS methods differ in terms of which DNA variants are included in the score and

the weights assigned to them. PGSs are evaluated in independent target samples of

individuals with known disease status. Evaluation of new PGS methods are made using

simulated data or single target cohort, however, in real data sets there can be heterogeneity

between target sample cohorts, which could reflect a number of real or artefactual factors.

The Psychiatric Genomics Consortium working groups for schizophrenia (SCZ) and major

depressive disorder (MDD) bring together many independently collected case-control cohorts

for GWAS meta-analysis. These resources are used here in repeated application of leave-one-

cohort-out GWAS analyses, generating robust conclusions for PGS prediction applied across

multiple target (left-out) cohorts. Eight PGS methods (P+T, SBLUP, LDpred-Inf, LDpred-

funct, LDpred, PRS-CS, PRS-CS-auto, SBayesR) are compared. We found that SBayesR had

the highest prediction evaluation statistics in most comparisons. For SCZ across 30 target

cohorts, the SBayesR PGS achieved a mean area under the receiver operator characteristic

curve (AUC) of 0.733, and explained 9.9% of variance on the liability scale. For MDD across

26 target cohorts, the AUC and variance explained were 0.601 and 4.0%, respectively. The

variance explained by the SBayesR PGS was 46% and 43% higher for SCZ and MDD,

respectively, compared to the basic p-value thresholding P+T method.

Introduction

Polygenic scores (PGSs), which assess the genetic risk of individuals for a disease[1; 2], are calculated as a weighted count of genetic risk alleles in the genome of an individual, with the risk alleles and their weights typically derived from the results of genome-wide association studies (GWAS).[3] PGS can be calculated for any trait or disease with sufficiently powered GWAS ('discovery samples'). For many common complex genetic disorders, such as cancers[4; 5] and heart disease[6; 7], there is increasing interest in trialling PGS for early disease detection, prevention and intervention[8; 9]. In the context of psychiatric disorders, it has been argued[10] that PGS may have utility in the context of youth mental health clinics, where young people present with symptoms that have not yet crystallised to portray a clear treatment pathway. A high PGS could nudge clinic decision making for those presenting in this prodromal state.

There are now many methods to calculate PGSs, and the methods differ in terms of two key criteria: which DNA variants to include (DNA variants here are limited to single nucleotide polymorphisms, SNPs, but can include other DNA variants tested for association with a trait) and what weights to allocate to them. While stringent thresholds are set to declare significance for association of individual SNPs in GWAS, PGSs are robust to inclusion of some false positives, and the maximum prediction from PGSs tested in target samples (i.e., GWAS samples independent of the GWAS discovery sample) may include nominally associated SNPs. The optimum method to decide which SNPs to select and what weights to allocate them, may differ between traits depending on the sample size of the discovery GWAS and on the genetic architecture of the trait (the number, frequencies and effect sizes of causal variants), particularly given the linkage disequilibrium (LD) structure between

SNPs. Often, when new PGS methods are introduced, comparisons are made between a

limited set of methods using simulated data, together with application to some real data

examples. However, it can be difficult to compare across the new methods, particularly

because in real data there can be heterogeneity in PGS evaluation statistics between target

samples, not encountered in idealised simulations. The reasons for this heterogeneity are

usually unknown but could reflect a number of factors such as phenotype definition,

ascertainment strategies of cases and controls, cohort-specific ancestry within the broad

classification of ancestry defined by the GWAS discovery samples (e.g., European), or

technical artefacts in genotype generation.

Here, we compare eight PGS methods (P+T[3; 11], SBLUP[12], LDpred-Inf[13], LDpred[13], LDpred-

funct[14], PRS-CS[15], PRS-CS-auto[15] and SBayesR[16] in **Table 1**). Some of these methods (P+T,

LDpred and PRS-CS) require a tuning sample, a GWAS cohort with known trait status that is

independent of both discovery and target samples, used to select parameters needed to

generate the PGSs in the target sample. Briefly, P+T (pruning with a p-value threshold) uses

the GWAS effect size estimates as SNP weights and includes independent SNPs (defined by

an LD r^2 filter for a given chromosomal window distance) with association p-values lower

than a threshold (chosen after application in a tuning sample). P+T is the most commonly

used and basic method, and so is the bench-mark method here. The other methods (referred to

here as recent methods) assume either that all SNPs have an effect size drawn from a normal

distribution (SBLUP and LDpred-Inf) or that SNP effects are drawn from mixtures of

distributions with the key parameters defining these architectures estimated through Bayesian

frameworks (LDpred, PRS-CS, SBayesR). LDpred-funct includes functional annotation to

SNPs to up/down weight their contributions to the PGSs, which could improve prediction

accuracy if this functional information helps to better separate true and false positive

associations[17]. We apply these methods to data from the Psychiatric Genomics Consortium

(PGC) working groups for schizophrenia (SCZ)[18; 19] and major depressive disorder (MDD)[20-

22] (**Tables S1 and S2**). The PGC provides a useful resource for undertaking this study

because it brings together many independently collected cohorts for GWAS meta-analysis.

This allows the application of repeated leave-one-cohort-out GWAS analyses generating

robust conclusions from evaluation of PGS applied across multiple left-out target cohorts.

Materials and Methods

Data:

Schizophrenia GWAS summary statistics, denoted as PGC-SCZ2+, were available from PGC

Schizophrenia (SCZ) Working group (34 European ancestry cohorts, denoted as SCZ34)[18]

and another three cohorts from Pardiñas et al[19]. PGC-SCZ2+ comprises more than 8M

imputed SNPs in 31K SCZ cases and 41K controls. Individual level genotype data were

available from 25K cases and 30K controls of SCZ34. Detailed information about the cohorts

is provided elsewhere[23] but is summarised in **Table S1**. Since some methods require a tuning

sample (defined below), we arbitrarily chose the lie2 cohort (137 cases and 269 controls) as

the tuning cohort. The GWAS discovery sample was a meta-analysis of 35 cohorts; lie2 was

always excluded and then each of the remaining 33 cohorts was left-out in turn and used as

the target sample. In sensitivity analyses, investigating the impact of the tuning sample, the

msaf, gras and swe6 cohort were exchanged with lie2 in turn, in which msaf has a similar

sample size as lie2, 327 cases and 139 controls, while gras and swe6 are larger with more

than 2000 individuals each.

Major depression GWAS summary statistics were available from seven studies including UK

Biobank[21; 24], 23andMe[25], GERA[26], iPSYCH[27], deCODE[28], GenScotland[29; 30], and the PGC

Major Depressive Disorder (MDD) Working group (with the data previously denoted as

PGC29, but here MDD29)[20]. All are European ancestry studies and comprise almost 13M

imputed SNPs from 248K cases and 563K controls. MDD29 includes the GWAS results from

29 research study cohorts. Detailed information of the MDD29 cohorts is described

elsewhere[20; 21; 25-30] but is summarised in **Table S2**. Individual level genotype data were

available for 15K cases and 24K controls from 26 cohorts. We left one cohort out of those 26

cohorts in turn as the target sample. A cohort from Muenster[20], not included in the MDD29

was used as the tuning sample (845 clinical defined MDD cases and 834 controls). We then

meta-analysed with the other GWAS summary statistics results to make the discovery

samples. We note that the discovery sample meta-analyses include samples where the

depression phenotype is self-reported rather than following a structured clinical interview,

nonetheless we refer to the prediction as MDD since the PGC target cohorts are of MDD

cases and controls. 959 overlapped individuals between UK Biobank and MDD29 were

excluded from the target cohorts.

The datasets stored in the PGC central server follow strict guidelines with local ethics

committee approval.

Baseline SNP selection

For baseline analyses, only SNPs with minor allele frequency (MAF) > 0.1 and imputation

INFO score > 0.9 (converted to best-guess genotype values of 0, 1 or 2) were selected.

Sensitivity analyses relaxed the MAF threshold to MAF > 0.05 or 0.01 and INFO score

threshold to 0.3. All methods were conducted using HapMap3 SNPs, except the method P+T,

which was conducted based on all imputed SNPs (8M in SCZ, and 13M in MDD).

Prediction methods

We define a PGS of an individual, *j*, as a weighted sum of SNP allele counts: $\sum_{i=1}^{m} \hat{b}_i x_{ij}$,

where *m* is the number of SNPs included in the predictor, $\hat{b}_i$ is the per allele weight for the

SNP, x_{ij} is a count of the number (0, 1, or 2) of trait-associated alleles of SNP *i* in individual

j. The cohort (target sample) for which PGSs are calculated is excluded from the meta-

analysis that generates the GWAS summary statistics (discovery sample), so that discovery

and target samples are independent. We compared eight risk prediction methods (detailed

below): The methods differ in terms of the SNPs selected for inclusion in the predictor and

the $\hat{b}_i$ values assigned to the SNPs. All methods use the GWAS summary statistics as the

starting point, but each makes choices differently for which SNPs to include and for the $\hat{b}_i$

values to assign. Briefly, the key differences between the methods are the assumptions made

about the underlying genetic architecture and the distributions of true effect sizes, with

Bayesian methods setting some priors for these distributions. Several methods employ an LD

reference sample to determine LD between SNPs. Here, we use EUR of the 1000 Genomes

Project as the LD reference, unless the method software provides an LD reference. In some

methods the PGS calculated in a target cohort requires estimates of parameter values, which

need to be estimated by application of the PGS method to a tuning cohort (also not included

in the discovery GWAS sample) using a range of parameter estimates, then selecting the

parameter estimates that maximizes prediction in that tuning cohort. In all methods, once the

SNPs and $\hat{b}_i$ have been decided, PLINK --*score* is used to calculate the PGS in the target

sample.

LD pruning and thresholding (P+T)[3]

In the P+T method GWAS summary statistics are pruned to be approximately independent

using a LD threshold, r^2. From this quasi-independent genome-wide SNP list, SNPs are

selected by thresholding on a pre-specified association p-value, P_t. We evaluated P+T as

implemented in Ricopili[31] which uses PLINK[32] to prune the SNP set using $r^2 = 0.1$ within

500 kb windows, and $P_t \in$ (5e-08, 1e-06, 1e-04, 1e-03, 0.01, 0.05, 0.1, 0.2, 0.5, 1), where $P_t =1$

means that all SNPs from the LD-pruned list are included. In applications of P+T it is

common for results from the most associated P_t to be reported (including the application in

the software PRSice[33] which uses a continuous P_t range), but this approach utilises

information from the target cohort and hence introduces a form of winner's curse. Here, the

P_t threshold applied in target cohorts is the P_t threshold that maximised prediction in the

tuning cohort.

SBLUP[12]

SBLUP is a method that re-scales the GWAS SNP effect estimates using an external LD

reference panel to transform the ordinary least-squares estimates to approximate the best

linear unbiased prediction (BLUP) solutions. This method assumes an infinitesimal model

where SNP effects are drawn from a normal distribution. All genome-wide SNPs are used to

build the PGS. Hence, for example, consider a genomic region with a single causal variant

but with many SNPs in the region correlated with the causal variant and correlated with each

other. In this case the effect size estimate is "smeared" across the correlated SNPs, but with

the total contribution to risk expected to represent the best estimate of the signal from the

underlying causal variant. This method is implemented within the software package GCTA[34].

LDpred and LDpred-inf [13]

While P+T uses arbitrary LD and p-value thresholds for selection of SNPs, LDpred tries to

optimise this step in a Bayesian framework. The method uses the GWAS summary statistics

and LD information from the external LD reference sample to infer the posterior mean effect

size of each SNP, conditioning on the SNP effect estimates of other correlated SNPs. This

method assumes a point-normal prior on the distribution of SNP effects such that only a

fraction of SNPs with non-zero estimated effects are selected for inclusion in the PGS. The

default parameter setting for the fractions of causal SNPs (π, but denoted p in the original

paper) were used in the tuning cohort: $\pi \in$ {1 (i.e. all SNPs), 0.3, 0.1, 0.03, 0.01, 0.003, and

0.001}, with an LD radius of M/3000 (M is the number of SNPs) to obtain local LD

information, as suggested by the authors[13]. The π value that maximised the prediction in the

tuning sample was applied in the target sample; the π value can differ between target cohorts

even though the same tuning cohort is used, reflecting the properties of the discovery sample

which may change with each left-out target sample. When π=1 the method is called LDpred-

Inf and is equivalent to SBLUP (the concordance of results was checked, **Table S7**).

LDpred-funct[14]

LDpred-funct is an extension of the LDpred-inf (SBLUP equivalent) model but leverages

trait-specific functional enrichments relative to the baseline-LD model[35] to up/down-weight

SNP effects. The functional annotations include coding, conserved, regulatory and LD-

related annotation. In the baseline-LD model, the enrichment of each category is jointly

calculated via stratified LD score regression[36]. LDpred-funct has a non-infinitesimal model

version, but in pilot analyses we found LDpred-Inf performed better than LDpred and hence

only considered the LDpred-funct infinitesimal model. Thus, we continued only with the

infinitesimal model version.

PRS-CS and PRS-CS-auto[15]

PRS-CS is also built under a Bayesian regression framework. Unlike LDpred which assumes

a point-normal distribution as a prior, which is discrete, PRS-CS assumes a continuous

shrinkage prior on the SNP effects. PRS-CS was implemented using the default setting and

with the LD reference panel provided with the PRS-CS software, which is computed using

the 1000 Genomes samples and HapMap3 SNPs. In PRS-CS, for the global scaling parameter

which is applied to all SNP effects ϕ, the search grid is $\phi^{1/2} \in \{0.0001, 0.001, 0.01, 0.1, 1\}$,

The ϕ that produces the best predictive performance in a tuning data set is selected for use in

the target sample. In PRS-CS-auto, ϕ is automatically learnt from GWAS summary statistics

and no tunning sample is needed.

SBayesR

SBayesR is a method that re-scales the GWAS SNP effect estimates based on Bayesian

multiple regression. SBayesR assumes that the standardised SNP effects are drawn from a

mixture of four zero-mean normal distributions with different variances (one of the variances

is zero, with a probability of π_1), indicating that only a fraction of SNPs $(1-\pi_1)$ have non-zero

estimated effects which contribute to the phenotype. Moreover, the contributions of SNPs in

different distributions differ because of different variances. Here, we evaluated SBayesR in

the default setting. For the LD reference, we used the same sparse LD matrix as the one used

in Lloyd-Jones et al.[16], where the LD matrix was built based on the HapMap3 SNPs of

randomly selected and unrelated 50K UK Biobank individuals. Whereas LDpred estimates

π from a tuning sample, SBayesR estimates π from the GWAS discovery sample, so no

tuning sample is needed.

Evaluation of out-of-sample prediction

The accuracy of prediction in each target cohort was quantified by 1) Area under the receiver

operator characteristic curve (AUC; R library pROC). AUC can be interpreted as a

probability that a case ranks higher than a control. 2) The proportion of variance on the

liability scale explained by PGS[37]. We used the population lifetime risk of SCZ and MDD as

1% and 15% respectively to convert the variance explained in a linear regression to the

liability scale[20; 23; 38]. 3) Odds ratio (OR) of tenth PGS decile relative to the first decile. 4)

Odds ratio of tenth PGS decile relative to those ranked in the middle of the PGS distribution,

which is calculated as the average of OR of tenth decile relative to fifth and sixth decile. 5)

Standard deviation unit increase in cases. The PGS in each target cohort were scaled by

standardising the PGS of controls and applying the standardisation to cases:

$\frac{PGS_{case} - mean(PGS_{control})}{SD(PGS_{control})}$, where SD is standard deviation. This does not impact PGS

evaluation statistics but simply means that PGS are in SD units for all cohorts. We compare

the median value for evaluation statistics 3 and 4, because they are significantly different

from a normal distribution based on a Shapiro-Wilk Normality Test. The regression analyses

for evaluation statistics 2-4 include 6 ancestry principal components as covariates. These

covariates are not included in the AUC model and the standard deviation unit increase in

cases model. To illustrate the impact on results, for SCZ given the SBayesR mean variance in

liability of 9.9% and lifetime risk of 0.01 the AUC expected from normal distribution

theory[39] is 0.730, compared to the mean reported of 0.733. For MDD given the variance in

liability of 4.0% and lifetime risk of 0.15 the expected AUC is 0.603 compared to the mean

reported of 0.601.

Results

Prediction evaluation statistics based on recent PGS methods applied to SCZ across 30 study

cohorts (**Figure 1**, **Table S3** and **S4**), and to MDD across 26 cohorts (**Figure 2, Table S5** and

S6), show higher values for all methods over the benchmark method, P+T. The evaluation

statistics include i) area under the receiver operator characteristic curve (AUC) which can be

interpreted as the probability that a case ranks higher than a control, when the case and

control are randomly drawn; ii) mean difference between cases and controls expressed in

PGS standard deviation (SD) units of controls, after standardization of the PGS so that

controls in each target cohort have a mean of 0 and a SD of 1; iii) variance in liability

explained by the PGS; iv) Odds ratio of the top 10% ranked on PGS relative to the bottom

10%; v) Odds ratio of the top 10% ranked on PGS relative to those ranking in the middle of

the PGS distribution; vi) difference between mean of PGS in the top 10% of cases and mean

PGS in top 10% of controls.

There is variability in prediction statistics across target cohorts which is not a reflection of

sample size (**Figure S1 and Table S4** for SCZ, **Figure S2 and Table S6** for MDD). To

provide a benchmark in terms of power, we note that for SCZ, the mean difference in PGS

between cases and controls for the P+T method is 0.73 standard deviation units of the control

sample (SDU). A sample size of only 42 cases and 42 controls has 95% power to detect this

difference at a nominal significance threshold of 0.05; all SCZ cohorts are bigger than this.

For MDD, the mean difference in PGS SDU between cases and controls for the P+T method

is 0.30, and the power calculation requires a sample size of 290 cases and 290 controls to

detect this difference; 20 (77%) of the MDD cohorts achieve this effective size. Hence, the

SCZ and MDD cohorts are well-powered for PGS evaluation.

The correlations of PGS between different methods are high (**Table S7**), but are lowest

between P+T and other methods (minimum 0.67). In contrast, the correlations between the

recent methods are always > 0.83. In theory, LDpred-Inf and SBLUP are the same method. In

practice, there are differences in implementation (e.g., different input parameters associated

with definition of LD window), generating a correlation 0.977. The differences in prediction

evaluation statistics between methods are small. For SCZ the AUC for all recent methods other than PRS-CS-auto are significantly higher than the P+T method after Bonferroni correction (p-value < 0.0018=0.05/28 (28 pair-wise comparisons between 8 methods), two-tailed Student's t-test). For MDD none of the differences between methods were significant. For both SCZ and MDD, regardless of tuning cohorts SBayesR showed relatively better performance (on average across target cohorts) than other methods on all statistics, where other recent methods performed similarly (**Figures 1 and 2**). For variance explained on the liability scale, the P+T PGS explained a mean of 6.8% across cohorts for SCZ. For SBayesR, the mean was 9.9% for variance explained in liability, an increase of 46%. For MDD although the variance explained is lower in absolute terms, 2.8% for P+T vs 4.0% for SBayesR; the latter represents a 43% increase.

We provide several evaluation statistics that focus on those in the top 10% of PGS, because clinical utility of PGS for psychiatric disorders is likely to focus on individuals that are in the top tail of the distribution of predicted genetic risk. The odds ratio for top vs bottom decile are large, ranging from 13.8 for P+T to 22.5 for SBayesR for SCZ and 3 to 4 for MDD. While these top vs bottom decile odds ratios (**Figure 1c** and **2c**) are much larger than the odds ratio obtained by using PGS to screen a general population (**Figure 1d** and **2d**) or patients in a healthcare system to identify people at high risk[40; 41], these comparisons are useful for research purposes, which could for example make cost-effective experimental designs focussing on individuals with high vs low PGS.[42] The odds ratio of top 10% vs middle 10% are much less impressive, up to median of 5.5 for SCZ and 2 for MDD, but more fairly represents the value of PGS in population settings. These values can be benchmarked against risk in 1st degree relatives of those affected, which are of the order of 8 for SCZ and 2 for MDD; low values are always expected for MDD because it is more common (lifetime risk

321 ~15% compared to ~1% for SCZ). The odds ratio values are particularly high for some

322 cohorts (**Table S4**), because in some SCZ cohorts the bottom 10% include very few or no

323 cases, especially in cohorts with relatively small sample sizes. Since the PGS are normally

324 distributed, as expected the mean PGS for controls in the top 10% PGS is ~1.75 SD units

325 (K=0.10, t=qnorm(1-K), z=dnorm(t), mean value of top 10% of a normal distribution =z/K),

326 whereas the top 10% of cases have mean value of 2.63 control sample SD units for SCZ

327 cases and 2.09 control sample SD units for MDD cases, using SBayesR. These mean values

328 of the top 10% in cases equate to expectations from the population of the top 1.1% and top

329 4.7% for SCZ and MDD, respectively.

331 **The impact of tuning cohort.** Three methods (i.e., P+T, LDpred and PRC-CS) use tuning

332 cohorts to determine key parameters for application of the method into the target cohorts.

333 Tuning parameters impact results in two ways. First, the parameters may be dependent on the

334 choice of tuning cohort. Second, the discovery GWAS sample may be reduced in size (and

335 hence power) if a tuning cohort needs to be excluded from the discovery GWAS. In all our

336 analyses the tuning cohort is excluded from all GWAS discovery samples so that GWAS

337 discovery sample is not variable across methods for each target cohort. A sensitivity analyses

338 that used the SCZ cohorts of msaf (Ncase= 327, Ncontrol= 139), gras (Ncase= 1086,

339 Ncontrol= 1232) or swe6 (Ncase= 1094, Ncontrol= 1219) as the tuning sample instead of

340 cohort lie2 (Ncase= 137, Ncontrol= 269) show that the tuning cohort can have considerable

341 impact (**Figure 3 and Figures S3-5**). In our results, the tuning cohort that generates higher

342 PGS is method dependent and differs between cohorts. Although methods SBLUP, LDpred-

343 Inf, LDpred-funct, PRS-CS-auto and SBayesR require no tuning cohort, they serve as a

344 benchmark, since the differences in their results reflect differences in the changed discovery

samples (e.g., msaf is in the discovery sample, when lie2 is the tuning cohort, and *vice versa*),

as well as the stochasticity inherent in the Gibbs sampling of Bayesian methods.

The impact of MAF/INFO threshold. A MAF threshold of 0.1 and a INFO threshold of 0.9

are used to be consistent with applications in the PGC SCZ[23] and PGC MDD[20] studies, which

had been imposed recognising that these thresholds generated more robust PGS results than

using lower threshold values. In the second sensitivity analysis applied to the SCZ data, the

MAF threshold was relaxed to 0.05 (**Figure 4)** and to 0.01 (**Figure S6**). The prediction

evaluation statistics increase for some cohorts and decrease for others. SBLUP, PRS-CS,

PRS-CS-auto and SBayesR are less affected than P+T, LDpred-Inf, LDpred-funct and

LDpred. For QC threshold of MAF < 0.01, the differences in AUC have a similar trend

compared to using MAF<0.05, but with greater variability (**Figure S6**). The effects of MAF

thresholds vary between cohorts, although the use of lower MAF threshold tends to generate

higher AUC for the larger target samples. Across target cohorts, different evaluation statistics

were almost identical when including less common SNPs (**Table S3**). Relaxing the INFO

score to 0.3 has a negligible effect (**Figure S7**).

Discussion

Comparison of PGS risk prediction methods showed that all recent methods had higher

prediction evaluation statistics over the benchmark P+T method for SCZ and MDD. While

the differences between the recent methods were small, we found that SBayesR consistently

ranked highest. Given that the PGS is a sum of many small effects, a normal distribution of

PGS in a population is expected (and observed **Figures S8-S11**). In idealised data, such as

the relatively simple simulation scenarios usually considered in method development, all

evaluation statistics should rank the same, but with real data sets this is not guaranteed. This

is the motivation for considering a range of evaluation statistics. Our focus on statistics for

those in the top 10% of PGS is partly motivated by potential clinical utility. In the context of

psychiatry, it is likely that this will focus on people presenting in a prodromal state with

clinical symptoms that have not yet crystallised to a specific diagnosis[10; 43]. High PGS in

those presenting to clinics could help tilt the clinical decision-making towards closer

monitoring or earlier intervention. Since a genetic-based predictor only predicts part of the

risk of disease, and since a PGS only predicts part of the genetic contribution to disease it is

acknowledged that PGS cannot be fully accurate predictors. Nonetheless, PGS, in

combination with clinical risk factors, could make a useful contribution to risk prediction.

In sensitivity analyses that used different quality criteria for SNPs e.g. MAF of 0.01 vs 0.05,

INFO of 0.3 vs 0.9, we concluded that, currently, there is little to be gained in PGS from

including SNPs with MAF < 0.10 and INFO < 0.9 for the diseases/dataset studied (**Table S8**

and **S9**). This result may seem counter-intuitive since variants with low MAF are expected to

play an important role in common disease, and some may be expected to have larger effect

sizes than more common variants[44; 45]. However, sampling variance is a function of allele

frequency (var(y)/(2*MAF(1-MAF)*n), where n is sample size), such that a variant of MAF

=0.01 has sampling variance 25 times greater than a variant of MAF=0.5. Moreover, in real

data sets cohort sample size and technical artefacts can accumulate to increase error in effect

size estimates particularly of low frequency variants. Our conclusion that little is gained from

including variants of MAF < 0.1 and reducing INFO threshold needs to be revisited as larger

discovery samples and larger target cohorts accumulate.

For both SCZ and MDD, while all recent methods had similar performance, SBayesR saw the

highest prediction accuracy in most of the comparisons. Although SCZ and MDD both have a

highly polygenic genetic architecture, we have recently shown that SBayesR outperforms

other methods for two less polygenic diseases, Alzheimer's[46] (which includes the *APOE*

locus which has a very large effect size) and ALS[47] (for which there is evidence of greater

importance of low MAF variants compared to SCZ[48]). The original SBayesR publication

showed that in both simulations and applications to real data, the method performed well

across a range of traits with different underlying genetic architectures, which is because

SBayesR can fit essentially any underlying architecture and other methods are special cases

of the SBayesR model, except PRS-CS which uses different distributional approaches (**Table**

1). We note that we did not consider a version of P+T that has been shown to have higher out

of sample prediction compared to the standard implementation[11]. This method conducts a

grid search in a tuning cohort to determine LD r^2 and INFO score thresholds for SNPs as well

as the p-value threshold. We chose to implement only the basic, commonly used P+T

method, and specifically as implemented in published PGC studies. Moreover, many of the

methods implemented here address optimum SNP selection from a methodological approach

rather than grid search approach. We note that here we only considered the infinitesimal

model version of LDpred-funct, because we have already found no advantage of LDpred over

LDpred-inf in the preliminary analyses. For traits and diseases of other genetic architecture

parameters of LDpref-funct should be investigated, although in the updated LDpred-funct

preprint[49], SBayesR was found to perform well across a range of quantitative and binary

traits. We do note that SBayesR expects effect size estimates and their standard errors to have

properties consistent with the sample size and with the LD patterns imposed from an external

reference panel. If GWAS summary statistics have non-ideal properties (perhaps resulting

from meta-analysis errors or approximations) then SBayesR may not achieve converged

solutions. Last, we note that the comparison of methods uses only study samples of European

ancestry. More research is needed to understand the properties of prediction methods within

other ancestries and across ancestries, given potential differences in genetic architectures (in

terms of number, frequencies and effect sizes of causal variants) and LD between measured

variants and causal variants[50; 51]. Such research is dependent on the availability of large

GWAS data sets from non-European ancestries; currently there is considerable effort to

increase GWAS sample collection across world-wide population groups to address this

concern[50-52].

All recent methods are compared using their default parameters settings. An optimum setting

of each method could potentially increase the prediction accuracy. For example, in sensitivity

analyses we found that LDpred sees higher prediction accuracy when increasing the length of

MCMC chain, while PRS-CS-auto and SBayesR results are not impacted by increasing the

MCMC chain length beyond the default settings (**Table S10**). This result agrees with the

recent revision of LDpred, LDpred2[53]. The underlying model and assumptions about the SNP

effect distribution are unchanged, but higher prediction accuracy is reported for longer

MCMC chain and larger LD windows. Most likely the optimum parameter settings are trait

(genetic architecture) dependent[11]. Hence, we conclude that a key advantage of SBayesR is

that there is no need for the user to tune or select model or software parameters. Moreover, it

does not need a tuning cohort to derive SNP effect weights but learns the genetic architecture

from the properties of the GWAS results. A third key advantage of SBayesR is computational

speed. Using one CPU, it takes approximately 2 hours to generate SNP weights based on

each discovery sample and predict into the left-out-cohort, compared to PRS-CS which needs

40 hours using 5 CPUs (the CPU number is fixed in the PRS-CS software). Last, given that

SBayesR uses only HapMap3 SNPs that are mostly well-imputed it should be possible to

provide these SBayesR SNP weights as part of a GWAS pipeline to apply in external target

samples.

Supplemental Data

The Supplemental Data include 11 figures and consortium members.

Acknowledgements

We acknowledge funding from the National health and Medical Research Council (1173790,1078901,108788 (NRW),1113400 (NRW, PMV)) and the Australian Research Council (FL180100072 (PMV)).

This work would not have been possible without the contributions of the investigators who comprise the PGC-SCZ and PGC-MDD working group. For a full list of acknowledgments of all individual cohorts included in PGC-SCZ and PGC-MDD, please see the original publications. The PGC has received major funding from the US National Institute of Mental Health and the US National Institute of Drug Abuse (U01 MH109528 and U01 MH1095320).

We thank the customers, research participants and employees of 23andMe for making this work possible. The study protocol used by 23andMe was approved by an external AAHRPP-accredited institutional review board.

The Münster cohort was funded by the German Research Foundation (DFG, grant FOR2107 DA1151/5-1 and DA1151/5-2 to U.D.; SFB-TRR58, Projects C09 and Z02 to U.D.) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Münster (grant Dan3/012/17 to U.D.).

Some data used in this study were obtained from dbGaP. dbGaP accession phs000021: funding support for the Genome-Wide Association of Schizophrenia Study was provided by the National Institute of Mental Health (R01 MH67257, R01 MH59588, R01 MH59571, R01 MH59565, R01 MH59587, R01 MH60870, R01 MH59566, R01 MH59586, R01 MH61675, R01 MH60879, R01 MH81800, U01 MH46276, U01 MH46289, U01 MH46318, U01

MH79469, and U01 MH79470), and the genotyping of samples was provided through the

Genetic Association Information Network (GAIN). Samples and associated phenotype data

for the Genome-Wide Association of Schizophrenia Study were provided by the Molecular

Genetics of Schizophrenia Collaboration (principal investigator P. V. Gejman, Evanston

Northwestern Healthcare (ENH) and Northwestern University, Evanston, IL, USA). dbGaP

accession phs000196: this work used in part data from the NINDS dbGaP database from the

CIDR: NGRC PARKINSON'S DISEASE STUDY. dbGaP accession phs000187: High-

Density SNP Association Analysis of Melanoma: Case–Control and Outcomes Investigation.

Research support to collect data and develop an application to support this project was

provided by P50 CA093459, P50 CA097007, R01 ES011740, and R01 CA133996 from the

NIH.

Statistical analyses were carried out on the Genetic Cluster Computer

(http://www.geneticcluster.org) hosted by SURFsara and financially supported by the

Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the

Dutch Brain Foundation and the VU University Amsterdam.

483   Declaration of Interests

484   The authors declare no competing interests.

485   References

1. The International Schizophrenia Consortium. (2009). Common polygenic variation
contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748-752.
2. Palk, A.C., Dalvie, S., De Vries, J., Martin, A.R., and Stein, D.J. (2019). Potential use of
clinical polygenic risk scores in psychiatry–ethical implications and communicating
high polygenic risk. Philos. Ethics Humanit. Med. 14, 4.
3. Wray, N.R., Goddard, M.E., and Visscher, P.M. (2007). Prediction of individual genetic risk
to disease from genome-wide association studies. Genome Res. 17, 1520-1528.
4. Jenkins, M.A., Win, A.K., Dowty, J.G., MacInnis, R.J., Makalic, E., Schmidt, D.F., Dite, G.S.,
Kapuscinski, M., Clendenning, M., and Rosty, C. (2019). Ability of known

susceptibility SNPs to predict colorectal cancer risk for persons with and without a
family history. Fam. Cancer 18, 389-397.

5. Lee, A., Mavaddat, N., Wilcox, A.N., Cunningham, A.P., Carver, T., Hartley, S., de Villiers,
C.B., Izquierdo, A., Simard, J., and Schmidt, M.K. (2019). BOADICEA: a comprehensive
breast cancer risk prediction model incorporating genetic and non-genetic risk
factors. Genet. Med. 21, 1708.

6. Khera, A.V., Chaffin, M., Aragam, K.G., Haas, M.E., Roselli, C., Choi, S.H., Natarajan, P.,
Lander, E.S., Lubitz, S.A., and Ellinor, P.T. (2018). Genome-wide polygenic scores for
common diseases identify individuals with risk equivalent to monogenic mutations.
Nat. Genet. 50, 1219-1224.

7. Lloyd-Jones, D.M., Wilson, P.W.F., Larson, M.G., Beiser, A., Leip, E.P., D'Agostino, R.B., and
Levy, D. (2004). Framingham risk score and prediction of lifetime risk for coronary
heart disease. Am. J. Cardiol. 94, 20-24.

8. McCarthy, M.I., and Mahajan, A. (2018). The value of genetic risk scores in precision
medicine for diabetes. Expert Rev. Precis. Med. Drug Dev. 3.

9. Torkamani, A., Wineinger, N.E., and Topol, E.J. (2018). The personal and clinical utility of
polygenic risk scores. Nat. Rev. Genet. 19, 581.

10. Murray, G.K., Lin, T., Austin, J., McGrath, J.J., Hickie, Ian B., and Wray, N.R. (2020).
Polygenic risk scores - could they be useful in psychiatry? Submitted.

11. Privé, F., Vilhjálmsson, B.J., Aschard, H., and Blum, M.G.B. (2019). Making the most of
Clumping and Thresholding for polygenic scores. Am. J. Hum. Genet. 105, 1213-1221.

12. Robinson, M.R., Kleinman, A., Graff, M., Vinkhuyzen, A.A.E., Couper, D., Miller, M.B.,
Peyrot, W.J., Abdellaoui, A., Zietsch, B.P., and Nolte, I.M. (2017). Genetic evidence of
assortative mating in humans. Nat. Hum. Behav. 1, 0016.

13. Vilhjálmsson, B.J., Yang, J., Finucane, H.K., Gusev, A., Lindström, S., Ripke, S., Genovese,
G., Loh, P.-R., Bhatia, G., and Do, R. (2015). Modeling linkage disequilibrium
increases accuracy of polygenic risk scores. Am. J. Hum. Genet. 97, 576-592.

14. Marquez-Luna, C., Gazal, S., Loh, P.-R., Furlotte, N., Auton, A., Price, A.L., and andMe
Research, T. (2018). Modeling functional enrichment improves polygenic prediction
accuracy in UK Biobank and 23andMe data sets. bioRxiv, 375337.

15. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C.A., and Smoller, J.W. (2019). Polygenic prediction via
Bayesian regression and continuous shrinkage priors. Nat. Commun. 10, 1776.

16. Lloyd-Jones, L.R., Zeng, J., Sidorenko, J., Yengo, L., Moser, G., Kemper, K.E., Wang, H.,
Zheng, Z., Magi, R., and Esko, T. (2019). Improved polygenic prediction by Bayesian
multiple regression on summary statistics. bioRxiv.

17. Chatterjee, N., Shi, J., and García-Closas, M. (2016). Developing and evaluating polygenic
risk prediction models for stratified disease prevention. Nat. Rev. Genet. 17, 392.

18. The International Schizophrenia Consortium. (2020). Manuscript in preparation.

19. Pardiñas, A.F., Holmans, P., Pocklington, A.J., Escott-Price, V., Ripke, S., Carrera, N.,
Legge, S.E., Bishop, S., Cameron, D., and Hamshere, M.L. (2018). Common
schizophrenia alleles are enriched in mutation-intolerant genes and in regions under
strong background selection. Nat. Genet. 50, 381-389.

20. Wray, N.R., Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E.M., Abdellaoui, A.,
Adams, M.J., Agerbo, E., Air, T.M., and Andlauer, T.M.F. (2018). Genome-wide
association analyses identify 44 risk variants and refine the genetic architecture of
major depression. Nat. Genet. 50, 668.

21. Howard, D.M., Adams, M.J., Clarke, T.-K., Hafferty, J.D., Gibson, J., Shirali, M., Coleman,
J.R.I., Hagenaars, S.P., Ward, J., and Wigmore, E.M. (2019). Genome-wide meta-
analysis of depression identifies 102 independent variants and highlights the
importance of the prefrontal brain regions. Nat. Neurosci. 22, 343.
22. Trzaskowski, M., Mehta, D., Peyrot, W.J., Hawkes, D., Davies, D., Howard, D.M., Kemper,
K.E., Sidorenko, J., Maier, R., and Ripke, S. (2019). Quantifying between-cohort and
between-sex genetic heterogeneity in major depressive disorder. American Journal
of Medical Genetics Part B: Neuropsychiatric Genetics 180, 439-447.
23. Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological
insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-427.
24. Howard, D.M., Adams, M.J., Shirali, M., Clarke, T.-K., Marioni, R.E., Davies, G., Coleman,
J.R.I., Alloza, C., Shen, X., and Barbu, M.C. (2018). Genome-wide association study of
depression phenotypes in UK Biobank identifies variants in excitatory synaptic
pathways. Nat. Commun. 9, 1-10.
25. Hyde, C.L., Nagle, M.W., Tian, C., Chen, X., Paciga, S.A., Wendland, J.R., Tung, J.Y., Hinds,
D.A., Perlis, R.H., and Winslow, A.R. (2016). Identification of 15 genetic loci
associated with risk of major depression in individuals of European descent. Nat.
Genet. 48, 1031.
26. Banda, Y., Kvale, M.N., Hoffmann, T.J., Hesselson, S.E., Ranatunga, D., Tang, H., Sabatti,
C., Croen, L.A., Dispensa, B.P., and Henderson, M. (2015). Characterizing
race/ethnicity and genetic ancestry for 100,000 subjects in the Genetic Epidemiology
Research on Adult Health and Aging (GERA) cohort. Genetics 200, 1285-1295.
27. Pedersen, C.B., Bybjerg-Grauholm, J., Pedersen, M.G., Grove, J., Agerbo, E., Baekvad-
Hansen, M., Poulsen, J.B., Hansen, C.S., McGrath, J.J., and Als, T.D. (2018). The
iPSYCH2012 case–cohort sample: new directions for unravelling genetic and
environmental architectures of severe mental disorders. Mol. Psychiatry 23, 6-14.
28. Ripke, S., Wray, N.R., Lewis, C.M., Hamilton, S.P., Weissman, M.M., Breen, G., Byrne,
E.M., Blackwood, D.H.R., Boomsma, D.I., and Cichon, S. (2013). A mega-analysis of
genome-wide association studies for major depressive disorder. Mol. Psychiatry 18,
497-511.
29. Smith, B.H., Campbell, A., Linksted, P., Fitzpatrick, B., Jackson, C., Kerr, S.M., Deary, I.J.,
MacIntyre, D.J., Campbell, H., and McGilchrist, M. (2012). Cohort Profile: Generation
Scotland: Scottish Family Health Study (GS: SFHS). The study, its participants and
their potential for genetic research on health and illness. Int. J. Epidemiol. 42, 689-
700.
30. Fernandez-Pujals, A.M., Adams, M.J., Thomson, P., McKechanie, A.G., Blackwood, D.H.R.,
Smith, B.H., Dominiczak, A.F., Morris, A.D., Matthews, K., and Campbell, A. (2015).
Epidemiology and heritability of major depressive disorder, stratified by age of
onset, sex, and illness course in Generation Scotland: Scottish Family Health Study
(GS: SFHS). PLoS One 10, e0142197.
31. Lam, M., Awasthi, S., Watson, H.J., Goldstein, J., Panagiotaropoulou, G., Trubetskoy, V.,
Karlsson, R., Frei, O., Fan, C.-C., De Witte, W., et al. (2019). RICOPILI: Rapid
Imputation for COnsortias PIpeLIne. Bioinformatics.
32. Chang, C.C., Chow, C.C., Tellier, L.C.A.M., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015).
Second-generation PLINK : rising to the challenge of larger and richer datasets.
GigaScience. 4.

33. Euesden, J., Lewis, C.M., and O'Reilly, P.F. (2015). PRSice: polygenic risk score software.
Bioinformatics 31, 1466-1468.
34. Yang, J., Lee, S.H., Goddard, M.E., and Visscher, P.M. (2011). GCTA: A tool for genome-
wide complex trait analysis. Am. J. Hum. Genet. 88, 76-82.
35. Gazal, S., Finucane, H.K., Furlotte, N.A., Loh, P.-R., Palamara, P.F., Liu, X., Schoech, A.,
Bulik-Sullivan, B., Neale, B.M., and Gusev, A. (2017). Linkage disequilibrium–
dependent architecture of human complex traits shows action of negative selection.
Nat. Genet. 49, 1421.
36. Finucane, H.K., Bulik-sullivan, B., Gusev, A., Trynka, G., Reshef, Y., Loh, P.-r., Anttila, V.,
Xu, H., Zang, C., Farh, K., et al. (2015). Partitioning heritability by functional
annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228-
1235.
37. Lee, S.H., Goddard, M.E., Wray, N.R., and Visscher, P.M. (2012). A better coefficient of
determination for genetic profile analysis. Genet. Epidemiol. 36, 214-224.
38. Lee, S.H., Wray, N.R., Goddard, M.E., and Visscher, P.M. (2011). Estimating missing
heritability for disease from genome-wide association studies. Am. J. Hum. Genet.
88, 294-305.
39. Wray, N.R., Lin, T., Austin, J., McGrath, J.J., Hickie, Ian B., Murray, G.K., and Visscher,
P.M. (2020). Polygenic risk scores – from basic science to clinical application: a
primer. JAMA Psychiatry (In press).
40. Zheutlin, A.B., Dennis, J., Karlsson Linnér, R., Moscati, A., Restrepo, N., Straub, P.,
Ruderfer, D., Castro, V.M., Chen, C.-Y., and Ge, T. (2019). Penetrance and pleiotropy
of polygenic risk scores for schizophrenia in 106,160 patients across four health care
systems. Am. J. Psychiatry 176, 846-855.
41. Binder, E.B. (2019). Polygenic Risk Scores in Schizophrenia: Ready for the Real World?
Am. J. Psychiatry 170, 783-784.
42. Rehbach, K., Zhang, H., Das, D., Abdollahi, S.S., Prorok, T., Ghosh, S., Weintraub, S.,
Genovese, G., Powell, S., and Lund, A. (2020). Publicly available hiPSC lines with
extreme polygenic risk scores for modeling schizophrenia. bioRxiv.
43. Perkins, D.O., Olde Loohuis, L., Barbee, J., Ford, J., Jeffries, C.D., Addington, J., Bearden,
C.E., Cadenhead, K.S., Cannon, T.D., and Cornblatt, B.A. (2020). Polygenic risk score
contribution to psychosis prediction in a target population of persons at clinical high
risk. Am. J. Psychiatry 177, 155-163.
44. Park, J.-H., Gail, M.H., Weinberg, C.R., Carroll, R.J., Chung, C.C., Wang, Z., Chanock, S.J.,
Fraumeni, J.F., and Chatterjee, N. (2011). Distribution of allele frequencies and effect
sizes and their interrelationships for common genetic susceptibility variants.
Proceedings of the National Academy of Sciences 108, 18026-18031.
45. Bomba, L., Walter, K., and Soranzo, N. (2017). The impact of rare and low-frequency
genetic variants in common disease. Genome Biol. 18, 77.
46. Zhang, Q., Visscher, P.M., and McRae, A.F. (2020). Risk prediction of late-onset
Alzheimer's disease implies an oligogenic architecture. Submitted.
47. Restuadi, R., Garton, F.C., Benyamin, B., and Lin, T. (2020). Polygenic Risk Score Analysis
for Amyotrophic Lateral Sclerosis leveraging Cognitive Performance, Educational
Attainment and Schizophrenia. Eur. J of Hum. Genet.
48. van Rheenen, W., Shatunov, A., Dekker, A.M., McLaughlin, R.L., Diekstra, F.P., Pulit, S.L.,
van der Spek, R.A., Võsa, U., de Jong, S., and Robinson, M.R. (2016). PARALS Registry.
SLALOM Group. SLAP Registry. FALS Sequencing Consortium. SLAGEN Consortium.

634   NNIPPS Study Group Genome-wide association analyses identify new risk variants
635   and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 48, 1043-
636   1048.

637 49. Márquez-Luna, C., Gazal, S., Loh, P.-R., Kim, S.S., and Furlotte, N. LDpred-funct:
638   incorporating functional priors improves polygenic prediction accuracy in UK Biobank
639   and 23andMe data sets.

640 50. Martin, A.R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B.M., and Daly, M.J. (2019).
641   Clinical use of current polygenic risk scores may exacerbate health disparities. Nat.
642   Genet. 51, 584.

643 51. Peterson, R.E., Kuchenbaecker, K., Walters, R.K., Chen, C.Y., Popejoy, A.B., Periyasamy,
644   S., Lam, M., Iyegbe, C., Strawbridge, R.J., Brick, L., et al. (2019). Genome-wide
645   Association Studies in Ancestrally Diverse Populations: Opportunities, Methods,
646   Pitfalls, and Recommendations. Cell 179, 589-603.

647 52. Karczewski, K.J., and Martin, A.R. (2020). Analytic and Translational Genetics. Annu. Rev.
648   Biomed. Data Sci. 3.

649 53. Privé, F., Arbel, J., and Vilhjálmsson, B.J. (2020). LDpred2: better, faster, stronger.
650   BioRxiv.

Figure

653
Figure 1. Results from prediction of SCZ case/control status using different PGS

methods.

a)   The area under curve (AUC) statistic. The AUC is a measure for the prediction accuracy,

which indicates the probability that a case ranks higher than a control. The predictors

were constructed from GWAS summary statistics of PGC-SCZ2+ excluding the target

cohort and the tuning cohort (cohort 'lie2'). Each bar reflects the mean AUC across 30

target cohorts, the whiskers show the 95% confidence interval for comparing means. The

number below each bar is the mean AUC estimated by each method, followed by its rank.

P+T is the benchmark method which is shown in orange. Pink shows the methods that use

an infinitesimal model assumption. Light green shows the methods using a tuning cohort

to determine the genetic architecture of a trait. Dark green shows the methods learning the

genetic architecture from discovery sample, without using a tuning cohort.

b) The proportion of variance explained by PGS on the scale of liability, assuming a

population lifetime risk of 1%.

c) The odds ratio when considering the odds of being a case comparing the top 10% vs

bottom 10% of PGS. The number below each violin is the median OR estimated by each

method, followed by its rank.

d) The odds ratio when considering the odds of being a case comparing the top 10% vs those

in the middle of the PGS distribution, calculated as the averaged odds ratio of the top

10% ranked on PGS relative to the 5th decile and 6th decile. The number below each

violin is the median OR estimated by each method, followed by its rank.

e) The mean of the PGS for the top 10% cases (coloured boxes) and for the top 10% of

controls (grey boxes) in PGS standard deviation (SD) unit scale so that controls have

mean PGS of zero and SD of 1.

f) This table shows the percentages of the number of cohorts (out of 30) where SBayesR

showed a higher prediction metric compared to different methods. AUC: Area under

curve; Variance explained: The proportion of variance explained by PGS in liability

scale; OR TvsB: odds ratio, comparing the top 10% vs bottom 10% of PGS; OR TvsM:

odds ratio, comparing the top 10% vs those in the middle of the PGS distribution; SD

increase: standard deviation units increasing of the PGS for the top 10% cases.

684

Figure 2. Results from prediction of MDD case/control status using different PGS

methods.

Similar to the caption of Figure 1, but the predictors were constructed from GWAS summary

statistics of UK Biobank[15], 23andMe[16], GERA[17], iPSYCH[18], deCODE[19], GenScotland[20,21],

PGC-MDD29 excluding the target cohort. The target cohorts comprised 26 of the 29 cohorts

in MDD29. A cohort from Muenster, not included in the MDD29 was used as the tuning

sample. The assumed population lifetime risk was 15% when estimating the proportion of

variance explained by MDD PGS in liability scale.

Figure 3. Sensitivity analyses using different tuning cohorts.

Differences in AUC of a PGS method when using different tuning cohorts. The different bars in each method (x-axis) refer to different validation cohorts ordered by sample size. The y-axis is the AUC difference when using alternative tuning cohort (i.e. msaf, sew6 or gras), compared to 'lie2'. The MAF QC threshold is 0.1. Note: SBLUP, LDpred-Inf and LDpred-funct, PRS-CS-auto and SBayesR do not need a tuning cohort, but serve as a benchmark to methods which need a tuning cohort. These methods differ when a different tuning cohort is left out, because the discovery GWAS also changes.

702
Figure 4. Sensitivity analyses using different MAF quality control thresholds.

Differences in AUC of a PGS method when using different MAF QC thresholds. The

different bars in each method (x-axis) refer to different validation cohorts ordered by sample

size. The y-axis is the AUC difference between analyses using MAF<0.05 and MAF <0.1 as

a QC threshold. The tuning cohort is 'lie2'.

Table

Table 1. Summary of methods used to generate PGS

Method	Distribution of SNP effects	Tuning sample	Pre-defined parameters	Parameters estimated in tuning sample
P+T	None	Yes	-	P value threshold
SBLUP	$\beta \sim N(0, \frac{h_g^2}{m})$ h_g^2: SNP-heritability, m: number of SNPs	No	M, h_g^2, LD radius in kb	-
LDpred-Inf	Same as SBLUP	No	Sample size, LD radius in number of SNPs	-
LDpred-funct	$\beta_j \sim N(0, c\sigma_j^2)$ $\sum_{j=1}^{M} 1_{\sigma_j^2 > 0} \, c\sigma_j^2 = h_g^2$, c is a normalizing constant σ_j^2 is the expected per SNP-heritability under the baseline-LD annotation model.	No	h_g^2, Per-SNP heritability estimated from stratified LDSC, Sample size, LD radius in number of SNPs	-
LDpred	$\beta_j \sim \begin{cases} N(0, \frac{h_g^2}{\pi m}), & \text{with probability of } \pi \\ 0, & \text{with probability of } 1 - \pi \end{cases}$	Yes	Sample size, LD radius in number of SNPs	π
PRS-CS	$\beta_j \sim N(0, \frac{\sigma^2}{n} \psi_j)$ $\psi_j \sim G(a, \delta_j)$ $\delta_j \sim G(b, \phi)$ ϕ is a global scaling parameter. n is sample size G is a Gamma distribution	Yes	a, b, Sample size	ϕ
PRS-CS-auto	Same as PRS-CS, but estimates ϕ from the discovery GWAS.	No	a, b, Sample size	-

SBayesR	$\beta_j \mid \pi, \sigma_\beta^2 \sim \begin{cases} 0, & \text{with probability of } \pi_1 \\ N(0, \gamma_2 \sigma_\beta^2), & \text{with probability of } \pi_2 \\ \vdots \\ N(0, \gamma_c \sigma_\beta^2), & \text{with probability of } 1 - \sum_{c=1}^{C-1} \pi_c \end{cases}$ $\sigma_\beta^2 \sim Inv - \chi^2(4)$ $\pi_i \sim Dir(\mathbf{1})$ γ_i are scaling parameters	No	γ_i	-

712 Distributions: N: normal, G: gamma, $Inv - \chi^2$: inverse chi-squared distribution, Dir: Dirichlet